Twitter hammered in pre-market trading as user growth disappoints
Apr 30, 2014 at 12:39 pm in General Trading by contrarianuk · Leave a Comment »
Apr 30, 2014 at 12:39 pm in General Trading by contrarianuk · Leave a Comment »
Apr 28, 2014 at 9:43 am in General Trading by contrarianuk · Leave a Comment »
Apr 26, 2014 at 8:10 am in General Trading by contrarianuk · 1 Comment »
Apr 24, 2014 at 9:37 am in General Trading by contrarianuk · Leave a Comment »
It was a big day for technology earnings in the United States after the market close last night with Facebook and Apple both reporting earnings. Apple’s shares rose nearly 8% to $564 on its fiscal second quarter earnings and Facebook rose 4.5% to $64 on first quarter earnings as both reported strong figures which helped reassure technology investors after the recent Nasdaq sell off.
Apr 20, 2014 at 3:28 pm in General Trading by contrarianuk · Leave a Comment »
Many investors are wondering whether this is the right time to start putting their money back into mining shares after an awful couple of years. The Blackrock World Mining Investment Trust is a good benchmark for performance of global mining companies with 11.6% of its assets in Rio Tinto, 11% in BHP Billiton and 9.7% in Glencore Xstrata.
Apr 11, 2014 at 8:20 am in Market Commentary by contrarianuk · Leave a Comment »
Apr 9, 2014 at 2:34 pm in AIM by contrarianuk · Leave a Comment »
Both companies saw their shares hit multi year low’s a couple of weeks ago with Xcite Energy disappointing investors with news that it had failed to tie up a farm out deal for its Bentley North Sea field, driving the price as low as 59p. In the case of GKP it was down to 80p following a statement in their bond offering document that the $250 million bond would be needed…
by contrarianuk
Big pharma in focus this morning as AstraZeneca and GSK grab the headlines
Apr 22, 2014 at 9:50 am in Market Commentary by contrarianuk · Leave a Comment »
Plenty of news today from big pharma with speculation surrounding a Pfizer/AstraZeneca tie up and a major announcement from GSK/Novartis on an asset swap. Both are an illustration that the sector is trying to find its way in an increasingly hostile regulatory environment, where drug development costs are now running in several billions per successful candidate.